-
艾媒咨询|2021-2022年中国医美器械产业运行及投资决策分析报告
本报告研究涉及企业/品牌/案例:科医人,复星医药,奇致激光,半岛医疗
伴随着医美市场规模的持续扩大,中国医美器械行业发展前景可期。数据显示,预计2021年中国医美器械市场规模将超过500亿元,同比增长27.8%。从细分赛道来看,近年来,微创和无创已逐渐成为医疗美容的趋势,这就推动了以激光、超声波等能量源为代表的光电类医美器械的发展。从市场格局来看,中国正规医美机构设备的市场份额80%是进口品牌,且中高端市场被飞顿、塞诺龙等海外龙头企业占领。为了改变这一局面,国家及地方先后出台政策鼓励本土医美器械品牌的发展,同时,国有品牌也通过加大自主研发投入和投资并购来扩大市场份额,未来随着下游扩张、需求渗透、技术更新等因素有望加速进口替代。
With the continuous expansion of the medical beauty market, the development prospect of the medical beauty equipment industry in China is promising. According to the data, it is estimated that in 2021, the market size of medical devices in China will exceed 50 billion yuan, with a year-on-year growth of 27.8%. From the perspective of subdivision, in recent years, minimally invasive and non-invasive have gradually become the trend of medical beauty, which promotes the development of photoelectric medical beauty devices represented by laser, ultrasonic and other energy sources. From the perspective of market structure, 80% of the market share of China's regular medical and beauty institutions' equipment is imported brands, and the medium and high-end market is occupied by overseas leading enterprises such as feton and sinolon. In order to change this situation, the state and local governments have successively issued policies to encourage the development of local medical and beauty equipment brands. At the same time, the state-owned brands also expand their market share by increasing independent R & D investment and investment in M & A. in the future, with the downstream expansion, demand penetration, technology update and other factors, it is expected to accelerate the import substitution. -
艾媒咨询|2021年中国轻医美行业研究及产业链分析报告
本报告研究涉及企业/品牌/案例:爱美客,华熙生物,奇致激光,华韩整形,新氧,兰州生物
数据显示,2020年中国轻医美用户市场规模达到1520万人,预计到2021年将增至1813万人。在消费意识觉醒和消费需求驱动下,机构、医生在供给端强势助推轻医美行业更快速发展,预计2021年中国轻医美市场将达到798亿元,同比增长46.4%。在行业快速增长的同时,轻医美产业链各环节企业由于集中度不同导致利润分配不均,具体来看,上游原料耗材企业由于高技术壁垒,市场集中度较高,毛利率高于中下游企业,如知名玻尿酸、肉毒素产品制造企业爱美客、华熙生物等,而中下游由于竞争分散,单体获利参差不齐,更容易产生乱象。但总体来说,在行业监管加强、机构自律、平台监督等多方力量共同作用下,轻医美行业将会向线上化、品牌化、规范化发展。
According to the data, the market size of China's light medical beauty users will reach 15.2 million in 2020, and it is expected to increase to 18.13 million by 2021. Driven by the awakening of consumer awareness and consumer demand, institutions and doctors strongly boost the rapid development of light medical beauty industry in the supply side. It is estimated that China's light medical beauty market will reach 79.8 billion yuan in 2021, with a year-on-year growth of 46.4%. With the rapid growth of the industry, the profit distribution of enterprises in each link of the light medical beauty industry chain is uneven due to different concentration. Specifically, due to high technical barriers, the upstream raw materials and consumables enterprises have higher market concentration and higher gross profit rate than the middle and downstream enterprises, such as the well-known hyaluronic acid, botulinum toxin product manufacturing enterprises aimekke, Huaxi biology, etc., while the middle and downstream enterprises have higher gross profit rate due to scattered competition, Individual profit is uneven, more likely to produce chaos. But on the whole, under the joint action of industry supervision, institutional self-discipline, platform supervision and other forces, the light medical beauty industry will develop to online, brand and standardization. -
艾媒报告|2019年12月-2020年1月中国医疗器械行业运行及上市公司双月度报告
本报告研究涉及企业/品牌包括:Mavidon,Titan Medical,Aspire Capital Fund,CentriMag,汇桥资本集团,联影医疗技术集团,医达极星,大博医疗,安捷伦,润扬医疗器械,迈瑞医疗,乐普医疗,威高医用,华大基因,安图生物,健帆生物,鱼跃医疗,京东方科技,美亚光电,东软集团,祥生医疗,硕世生物,佰仁医疗,爱博诺德,伟思医疗,安必平,林华医疗,拱东医疗,天智航,三友医疗,赛科希德等。
截至 2020 年 1 月 31 日 24:00,国家卫生健康委员会公布全国确诊病例 11791 例,重症病例 1795 例。短期来看,预计疫情将继续持续一段时间。肺炎疫情期间,病毒检测带动试剂盒需求增加;病毒治疗带动医用设备及医用耗材需求增加。部分医疗器械企业有望构成业绩增厚。
As of 24:00 on January 31, 2020, the National Health Commission announced 11791 confirmed cases and 1795 severe cases. In the short term, the outbreak is expected to continue for some time. During the pneumonia epidemic, virus detection drives demand for kits; virus treatment drives demand for medical equipment and supplies. Some medical device companies are expected to increase their performance. -
艾媒报告 |2019全球及中国口腔护理行业状况与发展趋势大数据分析报告
本报告研究涉及企业/品牌/案例:Straumann,invisalign,隐适美,美亚光电,BEGO,MISI,DENT,JUST,博恩登特,卡瓦集团,NewTom , Dentply Sirona , PLAMENCE , UEG MEDICAL, 泰康拜博口腔,北京大学口腔医院,拜瑞口腔,佳兆业健康集团,国瓷材料,土卓曼集团,牙医管家,茄子,武汉大学口腔医院,通策医疗,可恩口腔,牙博士口腔,阿里健康,一牙网,爱牙,牙医帮
2019年,中国5岁儿童及12岁儿童的龋齿患病率分别为70.9%和34.5%,成年人和老年人群体的牙周问题严重,中国居民口腔健康亟待改善。在国家政策的支持下,2010-2017年间,中国人均卫生费用涨至3738.8元,中国专科医院数量不断上升,口腔医院就诊人数增长到3587.6万人。从中国口腔市场的上下游产业链看,上游端器械市场以Straumann为代表的种植牙企业、典型正畸品牌隐适美以及CBCT巨头亚美广电均实现营收增长,分别于增长了20.7%、37.8%和36.1%;下游端,民营口腔机构达到6.5万个,占据14.2%的市场份额。艾媒咨询分析师认为,民营口腔医疗机构将成为未来中国口腔护理行业投资大市场,并且,“互联网+”和“商业保险+”的模式将逐渐普及。
In 2019, the prevalence of dental caries in Chinese 5-year-old children and 12-year-old children was 70.9% and 34.5%, respectively. Adults had severe periodontal problems, the bleeding rate of gingiva was 87.4%, and the detection rate of calculus was as high as 96.7%. Health needs to be improved. The National Health and Health Committee has established a clear indicator of oral health in 2020-2025. It is expected that the child prevalence rate will be controlled below 30.0%, and the number of remaining teeth in the elderly will reach 24. In 2010-2017, the per capita health expenditure in China rose to 3738.8 yuan. The number of specialized hospitals in China continued to rise. The stomatological hospitals had a large room for development. The number of patients in stomatological hospitals increased to 35.876 million, while the market for Chinese oral stocks was only 103.50 billion yuan. There is an incremental market with great potential. China's oral care upstream device market is expected to reach US$18.30 billion in 2022. The dental implant companies represented by Straumann, the typical orthodontic brand Invisialign and the CBCT giant Meyer all have achieved revenue growth, up 20.7% respectively. 37.8% and 36.1%. At the downstream end, the number of private dental institutions reached 65,000, accounting for 14.2% of the market. It represents the company's Taikang Baibo oral, joint commercial insurance and Internet platform, achieving one-stop service of “insurance + oral care”, as well as online and offline, the omni-channel service model, with revenue growth in 2017, reached 1.43 billion yuan. -
艾媒研报|科创板:2019年科创板受理企业及影子股分析研究报告
本报告研究涉及企业/品牌包括:科前生物、安翰科技、和舰芯片、容百科技、利元亨、江苏北人、天奈科技、睿创微纳、晶晨股份、贝斯达、华兴源创、微芯生物、特宝生物、国盾量子、虹软科技、世纪空间、光峰科技、福光股份、鸿泉物联、木瓜移动、优刻得、博众精工、创鑫激光、聚辰股份、海尔生物、天准科技、晶丰明源、申联生物、南微医学、美迪西、紫晶存储、苑东生物、恒安嘉新、乐鑫科技、龙软科技、杰普特、热景生物、瀚川智能、威胜信息、安博通、铂力特、视联动力、博瑞医药
2019年3月份科创板受理的企业包括:科前生物、安翰科技、和舰芯片、容百科技、利元亨、江苏北人、天奈科技、睿创微纳、晶晨股份、贝斯达、华兴源创、微芯生物、特宝生物、国盾量子、虹软科技、世纪空间、光峰科技、福光股份、鸿泉物联、木瓜移动等 2019年4月份受理的企业包括:优刻得、博众精工、创鑫激光、聚辰股份、海尔生物、天准科技、晶丰明源、申联生物、南微医学、美迪西、紫晶存储、苑东生物、恒安嘉新、乐鑫科技、龙软科技、杰普特、热景生物、瀚川智能、威胜信息、安博通、铂力特、视联动力、博瑞医药等,相应的重点影子股包括: TCL集团、华域汽车、天风证券、通化东宝、千方科技等。
In March and April 2019, the science and technology innovation board accepted the following enterprises: Wuhan Keqian Biology Co,Ltd, Ankon Technologies Co. Ltd, Hejian Technology (Suzhou) Co, Ltd, Ningbo Ronbay New Energy Technology Co, Ltd, Guangdong Lyric Robot Automation Co, Ltd, Jiangsu Beiren Robot System Co,Ltd, Jiangsu Cnano Technology Co, Ltd,Raytron Technology Co,Ltd,Amlogic (Shanghai) Co,Ltd, Shenzhen Basda Medical Apparatus Co,Ltd,Suzhou Hyc Technology Co,Ltd , etc. In April 2019, the science and technology innovation board accepted the following enterprises: Montage Technology Co, Ltd, UCloud Technology Co, Ltd, Bozhon Precision Industry Technology Co,Ltd, Shanghai Shen Lian Biomedical Corporation, Shanghai Bright Power Semiconductor Co, Ltd, Suzhou Tztek Technology Co,Ltd, Giantec Semiconductor Corporation, QINGDAO HAIER BIOMEDICAL CO, LTD. , MAXPHOTONICS Co, Ltd, Amethystum Storage Technology Co,Ltd , etc.
没找到想要的报告?
扫码添加客服参与预约/定制,第一时间获取行业推荐报告!
智库热榜
艾媒咨询|2024-2025年中国银发经济投资前景分析报告
艾媒咨询|2024-2025年中国烘焙食品行业现状及趋势研究报告
艾媒咨询 | 2023-2024年中国休闲食品产业现状及消费行为数据研究报告
艾媒咨询|2024-2025年全球及中国新能源汽车行业消费趋势监测与案例研究报告
艾媒咨询 | 2023-2024年中国全域旅游产业运行数据及发展趋势研究报告
艾媒咨询 | 2024年中国家用美容仪行业消费者洞察研究报告
艾媒咨询|赵一鸣零食店消费行为洞察及行业趋势报告(2024)
艾媒咨询|2024年中国月饼行业创新发展研究报告
艾媒咨询 | 2024年中国数字中台市场研究报告
艾媒咨询|2023-2024年全球及中国跨境电商运营数据及典型企业分析研究报告
艾媒咨询|2024年中国家清产品消费趋势洞察报告